• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美罗培南在高级器官支持(ADVOS)和连续肾脏替代治疗期间的药代动力学。

Pharmacokinetics of meropenem during advanced organ support (ADVOS) and continuous renal replacement therapy.

机构信息

Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Hospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

出版信息

Int J Artif Organs. 2021 Oct;44(10):783-786. doi: 10.1177/03913988211021101. Epub 2021 Jun 18.

DOI:10.1177/03913988211021101
PMID:34144656
Abstract

The advanced organ support (ADVOS) system allows to eliminate water-soluble as well as protein-bound molecules. Despite its clinical features, to date nothing is known about the elimination of clinically relevant drugs such as antiinfectives. Therefore, we report a case treated with ADVOS, continuous renal replacement therapy (CRRT), and meropenem (1 g 8-hourly) for empiric sepsis therapy monitored by meropenem drug levels. ADVOS showed more efficient elimination of meropenem compared to CRRT which has to be considered when evaluating dosing regimens.

摘要

高级器官支持(ADVOS)系统可清除水溶性和蛋白结合性分子。尽管 ADVOS 具有临床特点,但迄今为止,尚无关于其清除临床相关药物(如抗感染药物)的相关信息。因此,我们报告了 1 例使用 ADVOS、连续性肾脏替代治疗(CRRT)和美罗培南(1 g,8 小时 1 次)治疗经验性脓毒症患者的病例,通过美罗培南药物水平进行监测。与 CRRT 相比,ADVOS 显示出更有效的美罗培南清除率,在评估给药方案时应予以考虑。

相似文献

1
Pharmacokinetics of meropenem during advanced organ support (ADVOS) and continuous renal replacement therapy.美罗培南在高级器官支持(ADVOS)和连续肾脏替代治疗期间的药代动力学。
Int J Artif Organs. 2021 Oct;44(10):783-786. doi: 10.1177/03913988211021101. Epub 2021 Jun 18.
2
Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.系统评价模型指导下的重症患者连续肾脏替代治疗时美罗培南精准给药的药代动力学模型。
Antimicrob Agents Chemother. 2023 May 17;67(5):e0010423. doi: 10.1128/aac.00104-23. Epub 2023 May 1.
3
Transdermal Detection of MB-102 and Correlation to Meropenem Pharmacokinetics During Continuous Renal Replacement Therapy: In Vivo Results.经皮检测 MB-102 及其与连续肾脏替代治疗期间美罗培南药代动力学的相关性:体内研究结果。
ASAIO J. 2023 Jul 1;69(7):708-715. doi: 10.1097/MAT.0000000000001945. Epub 2023 Jun 27.
4
Poor Correlation between Meropenem and Piperacillin Plasma Concentrations and Delivered Dose of Continuous Renal Replacement Therapy.美罗培南和哌拉西林血浆浓度与持续肾脏替代治疗给药剂量之间的相关性较差。
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02029-20.
5
Population pharmacokinetics and probability of target attainment in patients with sepsis under renal replacement therapy receiving continuous infusion of meropenem: Sustained low-efficiency dialysis and continuous veno-venous haemodialysis.在接受美罗培南持续输注的肾替代治疗脓毒症患者中,群体药代动力学和目标达标概率:持续低效率透析和连续静脉-静脉血液透析。
Br J Clin Pharmacol. 2021 Nov;87(11):4293-4303. doi: 10.1111/bcp.14846. Epub 2021 May 4.
6
Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.肾清除率和连续肾脏替代治疗对有易感生命威胁感染的危重病患者推荐美罗培南给药方案适宜性的影响。
J Antimicrob Chemother. 2018 Dec 1;73(12):3413-3422. doi: 10.1093/jac/dky370.
7
Applicability and safety of discontinuous ADVanced Organ Support (ADVOS) in the treatment of patients with acute-on-chronic liver failure (ACLF) outside of intensive care.在重症监护之外,间断 ADVanced Organ Support(ADVOS)在治疗慢加急性肝衰竭(ACLF)患者中的适用性和安全性。
PLoS One. 2021 Apr 1;16(4):e0249342. doi: 10.1371/journal.pone.0249342. eCollection 2021.
8
The role of the ADVanced Organ Support (ADVOS) system in critically ill patients with multiple organ failure.ADVOS 系统在多器官衰竭危重症患者中的作用。
Artif Organs. 2022 May;46(5):735-746. doi: 10.1111/aor.14188. Epub 2022 Feb 6.
9
Advanced organ support (ADVOS) in the critically ill: first clinical experience in patients with multiple organ failure.危重症患者的高级器官支持(ADVOS):多器官衰竭患者的首次临床经验
Ann Intensive Care. 2020 Jul 16;10(1):96. doi: 10.1186/s13613-020-00714-3.
10
Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.采用高吸附膜行连续性静脉-静脉血液透析滤过的患者中,应用药代动力学/药效学群体分析法优化美罗培南剂量方案。
J Antimicrob Chemother. 2019 Oct 1;74(10):2979-2983. doi: 10.1093/jac/dkz299.

引用本文的文献

1
Meropenem plasma concentrations in critically ill patients treated with the novel multi organ replacement therapy ADVOS.采用新型多器官替代疗法ADVOS治疗的重症患者的美罗培南血浆浓度。
Infection. 2025 May 21. doi: 10.1007/s15010-025-02554-4.
2
elimination of antimicrobials during ADVanced Organ Support hemodialysis.在高级器官支持血液透析过程中抗菌药物的清除
Front Pharmacol. 2024 Dec 16;15:1447511. doi: 10.3389/fphar.2024.1447511. eCollection 2024.
3
The role of the ADVanced Organ Support (ADVOS) system in critically ill patients with multiple organ failure.
ADVOS 系统在多器官衰竭危重症患者中的作用。
Artif Organs. 2022 May;46(5):735-746. doi: 10.1111/aor.14188. Epub 2022 Feb 6.
4
Citrate pharmacokinetics in critically ill liver failure patients receiving CRRT.危重症肝衰竭患者行 CRRT 时枸橼酸盐的药代动力学。
Sci Rep. 2022 Feb 2;12(1):1815. doi: 10.1038/s41598-022-05867-8.